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Major histocompatibility class II (MHC II)-specific activation of CD4
+ T helper cells generates specific and persistent adaptive immunity against tumors. Emerging evidence demonstrates that MHC II is also involved in basic pain perception; however, little is known regarding its role in the development of cancer-induced bone pain (CIBP). In this study, we demonstrate that MHC II expression was markedly induced on the spinal microglia of CIBP rats in response to STAT1 phosphorylation. Mechanical allodynia was ameliorated by either pharmacological or genetic inhibition of MHC II upregulation, which was also attenuated by the inhibition of pSTAT1 and pERK but was deteriorated by intrathecal injection of IFNc. Furthermore, inhibition of ERK signaling decreased the phosphorylation of STAT1, as well as the production of MHC II in vivo and in vitro. These findings suggest that STAT1 contributes to bone cancer pain as a downstream mediator of ERK signaling by regulating MHC II expression in spinal microglia. Ó 2016 Elsevier Inc. All rights reserved.
Introduction
In 2016, 1,685,210 new cancer cases and an estimated 595,690 cancer deaths are projected to occur in the United States (Siegel et al., 2016) . Malignant tumors such as those in lung, prostate, and breast can undergo skeletal metastases that could result in severe cancer-induced bone pain, which substantially reduces the quality of life in cancer patients (Selvaraj et al., 2015) . Unfortunately, current treatments for bone cancer pain (BCP) are insufficient due to a lack of understanding of the underlying mechanisms.
Growing evidence suggests that the neuroimmune response plays a pivotal role in the development and maintenance of chronic pain (Dominguez et al., 2008; Grace et al., 2011; Sato-Takeda et al., 2006; Sweitzer and DeLeo, 2002) ; however, the precise mechanism is still largely unknown. Microglia are the resident macrophages of the central nervous system (CNS), which continuously survey the microenvironment. Any alteration of neuronal activity can induce specific microglial changes (Nimmerjahn et al., 2005) . Under chronic pain or neuroinflammatory conditions, microglial cells are activated and express high levels of major histocompatibility complex class II (MHC II). The most recognized function of MHC II is to be constitutively expressed on the surface of professional antigen-presenting cells loaded with antigenic peptide (Roche and Furuta, 2015) . Notably, many studies on the effects of spinal dorsal microglia suggest that MHC II may be a critical molecule in chronic neuropathic pain and autoimmune diseases (Hashizume et al., 2000; Lincoln et al., 2005; Sato-Takeda et al., 2006; Sweitzer et al., 2002) . Therefore, modulating the expression of MHC II in spinal microglia to inhibit maladaptive neuroimmune responses could be a potential therapeutic strategy for pain relief.
The Janus kinase/signal transducer and activator of transcription 1 (JAK/STAT1) signaling pathway is a key regulator of MHC II expression by modulating the expression of class II transactivator (CIITA) (Nikodemova et al., 2007; Ting and Trowsdale, 2002) . In particular, JAK/STAT1 signaling is not only activated by interferon c (IFNc) (Herrera-Molina et al., 2012; Muhlethaler-Mottet et al., 1998; Nikodemova et al., 2007; Zhou et al., 2015) but is also among the five pathways that lead to microglial activation (Graeber, 2010; Hanisch and Kettenmann, 2007; Smith, 2010) . To date, no direct evidence links the JAK/STAT1 signaling pathway to tactile allodynia under BCP conditions. We recently reported that ERK signaling is involved in the pathogenesis of BCP (Guan et al., 2015a) ; moreover,
